Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX: Olaparib and Durvalumab in Residual TNBC
NCT03740893Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Oct 2019
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab in triple-negative breast cancer (TNBC), sponsored by The Institute of Cancer Research. Started Oct 2019; status: recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03740893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740893.